UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
For the
month of September 2010
Commission
File Number: 001-34541
CHINA CORD BLOOD
CORPORATION
(Translation
of registrant’s name into English)
48th
Floor, Bank of China Tower
1 Garden
Road
Central
Hong Kong
S.A.R.
(Address
of Principal Executive Offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form 20-F
x Form
40-F ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ¨
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No
x
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-_______________.
Other
Events
On September 13, 2010, China Cord Blood
Corporation (the “Company”) issued a press release announcing that it intends to
conduct a share exchange with all existing warrant holders, in which the Company
will offer to exchange one ordinary share for every eight warrants.
A copy of the press release is attached as Exhibit 99.1.
Important
Information
This report and the description
contained herein are for informational purposes only and are not an offer to
purchase or a solicitation of an offer to sell securities of the Company. The
exchange offer described herein has not yet been commenced. At the time the
exchange offer is commenced, the Company intends to file a tender offer
statement on a Schedule TO containing an offer to exchange, a letter of
transmittal and other related documents with the Securities and Exchange
Commission (the “SEC”). Such documents will be mailed to warrant holders of
record and will also be made available for distribution to beneficial owners of
warrants of the Company. The solicitation of offers to exchange warrants for
ordinary shares of the Company will only be made pursuant to the offer to
exchange, the letter of transmittal and related documents. Warrant holders are
advised to read the offer to exchange, the letter of transmittal and all related
documents, if and when such documents are filed and become available, as they
will contain important information about the exchange offer and proposed warrant
exchange. Security holders can obtain these documents when they are filed and become
available free of charge from the SEC’s website at www.sec.gov. In addition,
copies of these documents and other filings containing information about the
Company may be obtained, if and when available, without charge, by directing a
request to China Cord Blood Corporation, Attention: Albert Chen, Chief Financial
Officer, at +852 3605 8180, or on the Company’s corporate website at
http://www.chinacordbloodcorp.com.
Exhibits
|
Exhibit No.
|
Description
|
|
|
99.1
|
|
Press
Release, dated September 13,
2010
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
CHINA
CORD BLOOD CORPORATION
|
|
|
By:
|
/s/ Albert Chen
|
|
Name:
|
Albert
Chen
|
|
Title:
|
Chief
Financial Officer
|
Dated:
September 13, 2010
China
Cord Blood Corporation to Launch Warrant Exchange Offer
Reduces
Potential Dilutive Effect of 13.2 Million Warrants
HONG KONG, China, September 13, 2010
- - China Cord Blood Corporation (“CCBC” or “the Company”) (NYSE: CO),
China’s leading provider of cord blood collection, laboratory testing,
hematopoietic stem cell processing, and stem cell storage services, today
announced its intention to conduct a share exchange with all existing warrant
holders, in which the Company will offer to exchange one ordinary share for
every eight warrants.
Ms. Ting
Zheng, Chairperson and CEO of China Cord Blood Corporation commented, “The
proposed exchange offer will streamline and simplify our shareholding structure
as well as corporate structure.”
China
Cord Blood Corporation had approximately 13,202,731 warrants and 67,039,796
ordinary shares issued and outstanding as of September 10, 2010. The
proposed exchange offer should significantly reduce the potential dilutive
effect, while also removing the significant equity overhang associated with the
warrants. Details of the exchange offer are expected to be available
shortly.
Ms. Ting
Zheng further commented, “We strive to be a responsible public
company. As we focus on delivering solid operational and financial
performance, we will not overlook the interests of our
shareholders. The proposed exchange offer is a balanced approach to
ensure that the interests of our Company, our shareholders and warrant holders
are all aligned.”
About
China Cord Blood Corporation
China
Cord Blood Corporation is the first and largest cord blood banking operator in
China in terms of geographical coverage and is the only cord blood bank operator
with multiple licenses. Under the current PRC government regulations,
only one licensed cord blood bank operator is permitted to operate in each
licensed region and only six licenses have been issued as of
today. China Cord Blood Corporation provides cord blood collection,
laboratory testing, hematopoietic stem cell processing, and stem cell storage
services. For more information, please visit our website at http://www.chinacordbloodcorp.com.
Important
Information
This
press release and the description contained herein are for informational
purposes only and are not an offer to purchase or a solicitation of an offer to
sell securities of the Company. The exchange offer described herein has not yet
been commenced. At the time the exchange offer is commenced, the Company intends
to file a tender offer statement on a Schedule TO containing an offer to
exchange, a letter of transmittal and other related documents with the
Securities and Exchange Commission (the “SEC”). Such documents will be mailed to
warrant holders of record and will also be made available for distribution to
beneficial owners of warrants of the Company. The solicitation of offers to
exchange warrants for ordinary shares of the Company will only be made pursuant
to the offer to exchange, the letter of transmittal and related documents.
Warrant holders are advised to read the offer to exchange, the letter of
transmittal and all related documents, if and when such documents are filed and
become available, as they will contain important information about the exchange
offer and proposed warrant exchange. Security holders can obtain these documents
when they are filed and become available free of charge from the SEC’s website
at www.sec.gov. In addition, copies of these documents and other filings
containing information about the Company may be obtained, if and when available,
without charge, by directing a request to China Cord Blood Corporation,
Attention: Albert Chen, Chief Financial Officer, at +852 3605 8180, or on the
Company’s corporate website at http://www.chinacordbloodcorp.com.
Safe
Harbor Statement
This
press release contains forward-looking statements as defined by the Private
Securities Litigation Reform Act of 1995. Forward-looking statements include
statements concerning plans, objectives, goals, strategies, future events,
performance and results of operations, and underlying assumptions and other
statements that are other than statements of historical facts. These statements
are subject to uncertainties and risks including, but not limited to, product
and service demand and acceptance, changes in technology, economic conditions,
the impact of competition and pricing, government regulation, and other risks
contained in statements filed from time to time with the Securities and Exchange
Commission. All such forward-looking statements, whether written or oral, and
whether made by or on behalf of the Company, are expressly qualified by the
cautionary statements and any other cautionary statements which may accompany
the forward-looking statements. In addition, the Company disclaims any
obligation to update any forward-looking statements to reflect events or
circumstances after the date hereof.
For
more information, please contact:
China
Cord Blood Corporation
Ms.
Joeling Law
Tel:
(+852) 3605-8180
Email:
[email protected]
ICR,
LLC
In New
York: Ashley M. Ammon or Christine Duan: 1-646-277-1227
In
Beijing: Wen Lei Zheng: +86-10-6599-7968